| Umsatz in Mio. | 1,00 $ |
| Operatives Ergebnis (EBIT) in Mio. | -22,41 $ |
| Jahresüberschuss in Mio. | -19,99 $ |
| Umsatz je Aktie | 0,12 $ |
| Gewinn je Aktie | -2,40 $ |
| Gewinnrendite | -67,58% |
| Umsatzrendite | - |
| Return on Investment | -57,10% |
| Marktkapitalisierung in Mio. | 24,82 $ |
| KGV (Kurs/Gewinn) | -1,24 |
| KBV (Kurs/Buchwert) | 0,84 |
| KUV (Kurs/Umsatz) | 24,83 |
| Eigenkapitalrendite | - |
| Eigenkapitalquote | +84,48% |
| Geld/Brief | 1,61 € / 1,77 € |
| Spread | +9,94% |
| Schluss Vortag | 1,66 € |
| Gehandelte Stücke | 0 |
| Tagesvolumen Vortag | - |
| Tagestief 1,61 € Tageshoch 1,61 € | |
| 52W-Tief 1,55 € 52W-Hoch 3,66 € | |
| Jahrestief 1,55 € Jahreshoch 3,66 € | |
| Handelsplatz | Letzter | Änderung | Vortag | Zeit | |
|---|---|---|---|---|---|
| Düsseldorf | 1,64 € | -4,09% | 1,71 € | 08:11 | |
| Frankfurt | 1,61 € | -3,01% | 1,66 € | 08:14 | |
| München | 1,70 € | 0 % | 1,70 € | 08:00 | |
| Stuttgart | 1,63 € | -3,55% | 1,69 € | 07:30 | |
| L&S RT | 1,69 € | 0 % | 1,69 € | 09:15 | |
| Berlin | 1,69 € | -2,87% | 1,74 € | 08:23 | |
| NYSE | 2,055 $ | 0 % | 2,055 $ | 26.11.25 | |
| Nasdaq | 2,025 $ | -1,22% | 2,05 $ | 05.12.25 | |
| AMEX | 2,03 $ | +0,50% | 2,02 $ | 18.11.25 | |
| Tradegate | 1,66 € | -4,05% | 1,73 € | 03.12.25 | |
| Quotrix | 1,69 € | -2,87% | 1,74 € | 07:27 | |
| Gettex | 1,66 € | -2,92% | 1,71 € | 09:14 | |
| Datum | Kurs | Volumen |
|---|---|---|
| 05.12.25 | 1,66 | 0 |
| 04.12.25 | 1,57 | 0 |
| 03.12.25 | 1,55 | 0 |
| 02.12.25 | 1,65 | 0 |
| 01.12.25 | 1,71 | 0 |
| Zeitraum | Kurs | % |
|---|---|---|
| 1 Woche | 1,69 € | -1,78% |
| 1 Monat | 2,08 € | -20,19% |
| 6 Monate | 2,24 € | -25,89% |
| 1 Jahr | 2,52 € | -34,13% |
| 5 Jahre | 19,20 € | -91,35% |
| Marktkapitalisierung | 15,38 Mio. € |
| Aktienanzahl | 8,39 Mio. |
| Streubesitz | 71,00% |
| Währung | EUR |
| Land | USA |
| Sektor | Gesundheit |
| Branche | Biotechnologie |
| Aktientyp | Stammaktie |
| +2,90% | Vanguard Group Inc |
| +2,40% | BML Capital Management LLC |
| +1,17% | Renaissance Technologies Corp |
| +0,70% | Geode Capital Management, LLC |
| +0,63% | BlackRock Inc |
| +0,29% | Dimensional Fund Advisors, Inc. |
| +0,16% | State Street Corp |
| +0,14% | HPM Partners LLC |
| +0,12% | Bank of America Corp |
| +0,12% | Northern Trust Corp |
| +0,11% | HighTower Advisors, LLC |
| +0,08% | UBS Group AG |
| +0,07% | Royal Bank of Canada |
| +0,02% | Founders Capital Management Inc |
| +0,02% | Tower Research Capital LLC |
| +0,00% | Morgan Stanley - Brokerage Accounts |
| +0,00% | SBI Securities Co Ltd |
| 0,00% | Barclays PLC |
| 0,00% | Cheviot Value Management, Inc. |
| 0,00% | Wells Fargo & Co |
| +20,06% | Weitere |
| +71,00% | Streubesitz |
Zahlen für Q2/24
- Phase 2b ASCEND trial top-line data remains on track to be reported in fourth quarter of 2024
-Available cash projected to fund current operations into early 2026 and all active studies through to data